{"id":55305,"date":"2023-03-29T14:05:18","date_gmt":"2023-03-29T12:05:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/"},"modified":"2023-03-29T14:05:18","modified_gmt":"2023-03-29T12:05:18","slug":"epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/","title":{"rendered":"Epic Bio to Participate in the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days"},"content":{"rendered":"
\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Epic Bio<\/a>, a leading epigenome engineering company developing therapies to modulate gene expression using ultracompact, non-cutting dCas proteins, today announced that the company will participate in the Guggenheim Healthcare Talks – Genomic Medicine and Rare Disease Days, April 3-4, 2023, in New York, NY. The company will also hold meetings with investors and analysts during the event.\n<\/p>\n

<\/a><\/p>\n

\nAmber Salzman, Ph.D., Epic Bio\u2019s chief executive officer, is scheduled to participate in a panel on genomic medicines and rare diseases on Monday, April 3, 2023, from 1:00 \u2013 2:00 p.m. ET.\n<\/p>\n

\nAbout Epic Bio<\/b>\n<\/p>\n

\nEpic Bio is a leading epigenome engineering company, leveraging the power of CRISPR without cutting DNA. The company is using its proprietary Gene Expression Modulation System (GEMS) to develop therapies. Through the company\u2019s library of the most compact Cas DNA-binding proteins to work on human cells, the company is developing in vivo therapies leveraging delivery via a single AAV or LNP. Epic Bio has an initial focus on Facioscapulohumeral Muscular Dystrophy (FSHD) and is conducting additional research to address Antitrypsin Deficiency (A1AD), Heterozygous Familial Hypocholesterolemia (HeFH), as well as other indications. The company is financially backed by Horizons Ventures and other leading investors. Visit www.epic-bio.com<\/a> for more information or follow us on Twitter<\/a> and LinkedIn<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact<\/b>\n<\/p>\n

\nShawn M. Cox
\n
Manager, Investor Relations, Corporate Communications
\n
Epic Bio
\n
shawn.cox@epic-bio.com<\/a>\n<\/p>\n

\nMedia Contact<\/b>\n<\/p>\n

\nLisa Raffensperger
\n
Ten Bridge Communications
\n
lisa@tenbridgecommunications.com<\/a>
(617) 903-8783\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Epic Bio, a leading epigenome engineering company developing therapies to modulate gene expression using ultracompact, non-cutting dCas proteins, today announced that the company will participate in the Guggenheim Healthcare Talks – Genomic Medicine and Rare Disease Days, April 3-4, 2023, in New York, NY. The company will also hold meetings with … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55305","6":"format-standard","7":"category-industry"},"yoast_head":"\nEpic Bio to Participate in the Guggenheim Healthcare Talks - Genomic Medicines and Rare Disease Days - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Epic Bio to Participate in the Guggenheim Healthcare Talks - Genomic Medicines and Rare Disease Days - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Epic Bio, a leading epigenome engineering company developing therapies to modulate gene expression using ultracompact, non-cutting dCas proteins, today announced that the company will participate in the Guggenheim Healthcare Talks – Genomic Medicine and Rare Disease Days, April 3-4, 2023, in New York, NY. The company will also hold meetings with ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-29T12:05:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230328005952\/en\/1593825\/21\/EpicBioCMYK300dpi.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Epic Bio to Participate in the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days\",\"datePublished\":\"2023-03-29T12:05:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/\"},\"wordCount\":259,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005952\\\/en\\\/1593825\\\/21\\\/EpicBioCMYK300dpi.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/\",\"name\":\"Epic Bio to Participate in the Guggenheim Healthcare Talks - Genomic Medicines and Rare Disease Days - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005952\\\/en\\\/1593825\\\/21\\\/EpicBioCMYK300dpi.jpg\",\"datePublished\":\"2023-03-29T12:05:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005952\\\/en\\\/1593825\\\/21\\\/EpicBioCMYK300dpi.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230328005952\\\/en\\\/1593825\\\/21\\\/EpicBioCMYK300dpi.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Epic Bio to Participate in the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Epic Bio to Participate in the Guggenheim Healthcare Talks - Genomic Medicines and Rare Disease Days - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/","og_locale":"en_US","og_type":"article","og_title":"Epic Bio to Participate in the Guggenheim Healthcare Talks - Genomic Medicines and Rare Disease Days - Pharma Trend","og_description":"SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Epic Bio, a leading epigenome engineering company developing therapies to modulate gene expression using ultracompact, non-cutting dCas proteins, today announced that the company will participate in the Guggenheim Healthcare Talks – Genomic Medicine and Rare Disease Days, April 3-4, 2023, in New York, NY. The company will also hold meetings with ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-29T12:05:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230328005952\/en\/1593825\/21\/EpicBioCMYK300dpi.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Epic Bio to Participate in the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days","datePublished":"2023-03-29T12:05:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/"},"wordCount":259,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230328005952\/en\/1593825\/21\/EpicBioCMYK300dpi.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/","url":"https:\/\/pharma-trend.com\/en\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/","name":"Epic Bio to Participate in the Guggenheim Healthcare Talks - Genomic Medicines and Rare Disease Days - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230328005952\/en\/1593825\/21\/EpicBioCMYK300dpi.jpg","datePublished":"2023-03-29T12:05:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230328005952\/en\/1593825\/21\/EpicBioCMYK300dpi.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230328005952\/en\/1593825\/21\/EpicBioCMYK300dpi.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/epic-bio-to-participate-in-the-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Epic Bio to Participate in the Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55305"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55305\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}